Non-Hodgkin Lymphoma Diagnostics Market By Type (Lymph Node Biopsy (Immunophenotyping, Cytogenetic Analysis, Gene Expression Profiling, Microarray analysis), Physical Imaging (MRI Scanning, CT-Scan, X-rays, Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), Blood Tests)), By Type of NHL (B-Cell Non-Hodgkin Lymphoma (Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Mantel Cell Lymphoma, Primary Central Nervous System Lymphoma), T-Cell Non-Hodgkin Lymphoma (Peripheral T-Cell Lymphoma not Otherwise Specified, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Adult T-Cell Lymphoma, Nasal type NK/T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma), By Category of Condition (Category A, Category B, Category X, Category E), By End User (Hospitals, Diagnostic Centers, Clinics), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021 and is expected to grow at a CAGR of 10.8% from 2023-2029. Several factors, such as AIDS infection, immunosuppressive medications, occupational exposures, pesticide proximity, and smoking, are key risk factors for the development of NHL. With around 4% of all cancer cases in the US, non-Hodgkin lymphoma (NHL) is one of the most prevalent tumours. According to the American Cancer Society, there will be an estimated, NHL will be identified in about 80,470 persons (44,120 men and 36,350 women). Adults and children are both included in this.

Non-Hodgkin lymphoma is the second most frequent cancer in people with HIV, and some people with AIDS also have lymphoma. It is true that non-Hodgkin lymphoma patients should routinely undergo HIV and hepatitis virus screenings. A thorough assessment of the burden brought on by malignancies was made by the Global Burden of Disease study (GBDs), which made it easier to monitor the temporal patterns in the disease burden. The idea that there is a connection between obesity and NHL has been supported by concurrent rises in the prevalence of obesity and the incidence of NHL during the past few decades. The prognosis for those who have non-lymphoma Hodgkin's has improved as a result of improvements in diagnosis and therapy. Researchers are investigating ways to avoid infections such HHV-8, HIV, HTLV-1, and H. pylori that have been linked to non-Hodgkin lymphoma. The chance of getting non-Hodgkin lymphoma may be decreased by avoiding exposure to certain substances, such as lead, arsenic, pesticides, vinyl chloride, and asbestos.

Non-Hodgkin Lymphoma Diagnostics Market Key Developments:

In May 2021, PerkinElmer, Inc. purchased Immunodiagnostic Systems Holdings PLC in order to grow its overall diagnostics business for about $155 million.

Global Non Hodgkin Lymphoma Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

10.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Non-Hodgkin Lymphoma Diagnostics Market Dynamics

Growing awareness and concern about the disease, increase in healthcare expenditure, rise in advancements in the technologies and innovation of new products, large number of unmet needs related to the disease are the few factors which are propelling the growth of the Non-Hodgkin lymphoma diagnostics market. However, limited options for the treatment, inaccurate and inadequate results of the diagnosis, high cost associated with the tests are the few factors which are restraining the growth of the Non-Hodgkin lymphoma diagnostics market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Non Hodgkin Lymphoma Diagnostics Market Segmentation

By Type
  • Lymph Node Biopsy
  • Immunophenotyping
  • Cytogenetic Analysis
  • Gene Expression Profiling
  • Microarray analysis
  • Physical Imaging
  • MRI Scanning
  • CT-Scan
  • X-rays
  • Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
  • Blood Tests
By Type of NHL
  • B-Cell Non-Hodgkin Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Burkitt Lymphoma
  • Mantel Cell Lymphoma
  • Primary Central Nervous System Lymphoma
  • T-Cell Non-Hodgkin Lymphoma
  • Peripheral T-Cell Lymphoma not Otherwise Specified
  • Anaplastic Large Cell Lymphoma
  • Angioimmunoblastic T-Cell Lymphoma
  • Enteropathy-Associated T-Cell Lymphoma
  • Adult T-Cell Lymphoma
  • Nasal type NK/T-Cell Lymphoma
  • Hepatosplenic T-Cell Lymphoma
By Category-Condition
  • Category A
  • Category B
  • Category X
  • Category E
By End User
  • Hospitals
  • Diagnostic Centers
  • Clinics

Frequently Asked Questions

The Non-Hodgkin Lymphoma Diagnostics Market size was valued at USD 12149.12 million in 2021

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The non hodgkin lymphoma diagnostics market key players are Novartis AG (Switzerland), Amgen, Inc.(U.S), Abbott Laboratories, Inc.(U.S), Eli Lilly and Company(U.S.), AstraZeneca plc (U.K)

1. Executive Summary
2.  Global Non-Hodgkin Lymphoma Diagnostics Market Introduction 
2.1. Global Non-Hodgkin Lymphoma Diagnostics Market  - Taxonomy
2.2. Global Non-Hodgkin Lymphoma Diagnostics Market  - Definitions
2.2.1. By Type
2.2.2. By Type of NHL
2.2.3. By Category of Condition
2.2.4. By End User
2.2.5. By Region
3. Global Non-Hodgkin Lymphoma Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Key Developments
4. Global Non-Hodgkin Lymphoma Diagnostics Market  By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
4.1. Lymph Node Biopsy
4.1.1. Immunophenotyping
4.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.1.3. Market Opportunity Analysis 
4.1.2. Cytogenetic Analysis
4.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.2.3. Market Opportunity Analysis 
4.1.3. Gene Expression Profiling
4.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.3.3. Market Opportunity Analysis 
4.1.4. Microarray Analysis
4.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.1.4.3. Market Opportunity Analysis 
4.2. Physical Imaging
4.2.1. MRI Scanning
4.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.1.3. Market Opportunity Analysis 
4.2.2. CT-Scan
4.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.2.3. Market Opportunity Analysis 
4.2.3. X-rays
4.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.3.3. Market Opportunity Analysis 
4.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
4.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.2.4.3. Market Opportunity Analysis 
4.3. Blood Tests
4.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
4.3.3. Market Opportunity Analysis 
5. Global Non-Hodgkin Lymphoma Diagnostics Market  By Type of NHL, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1.  B-Cell Non-Hodgkin Lymphoma
5.1.1. Diffuse Large B-Cell Lymphoma
5.1.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.1.3. Market Opportunity Analysis 
5.1.2. Burkitt Lymphoma
5.1.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.2.3. Market Opportunity Analysis 
5.1.3. Mantel Cell Lymphoma
5.1.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3.3. Market Opportunity Analysis 
5.1.4. Primary Central Nervous System Lymphoma
5.1.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.4.3. Market Opportunity Analysis 
5.2. T-Cell Non-Hodgkin Lymphoma
5.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
5.2.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.1.3. Market Opportunity Analysis 
5.2.2. Anaplastic Large Cell Lymphoma
5.2.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.2.3. Market Opportunity Analysis 
5.2.3. Angioimmunoblastic T-Cell Lymphoma
5.2.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3.3. Market Opportunity Analysis 
5.2.4. Enteropathy-Associated T-Cell Lymphoma
5.2.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.4.3. Market Opportunity Analysis 
5.2.5. Adult T-Cell Lymphoma
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.5.3. Market Opportunity Analysis 
5.2.6. Nasal type NK/T-Cell Lymphoma
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.5.3. Market Opportunity Analysis 
5.2.7. Hepatosplenic T-Cell Lymphoma
5.2.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.5.3. Market Opportunity Analysis 
6. Global Non-Hodgkin Lymphoma Diagnostics Market By Category of Condition, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Category A
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Category B
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3.  Category X
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Category E
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7. Global Non-Hodgkin Lymphoma Diagnostics Market  By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Hospitals
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) 
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.1.3. Market Opportunity Analysis  
7.2. Diagnostic Centers 
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) 
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.2.3. Market Opportunity Analysis  
7.3. Clinics 
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) 
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)  
7.3.3. Market Opportunity Analysis  
8.  Global Non-Hodgkin Lymphoma Diagnostics Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. MEA
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
8.6.  Global Non-Hodgkin Lymphoma Diagnostics Market - Opportunity Analysis Index, By Type of NHL, Type, Category of Condition, End User,  ,  ,  , and Region, 2023-2029
9. North America Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1. Lymph Node Biopsy
9.1.1.1. Immunophenotyping 
9.1.1.2. Cytogenetic Analysis
9.1.1.3. Gene Expression Profiling
9.1.1.4. Microarray Analysis
9.1.2. Physical Imaging
9.1.2.1. MRI Scanning
9.1.2.2. CT-Scan
9.1.2.3. X-rays
9.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
9.1.3. Blood Tests
9.2. Type of NHL Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.  B-Cell Non-Hodgkin Lymphoma
9.2.1.1. Diffuse Large B-Cell Lymphoma 
9.2.1.2. Burkitt Lymphoma
9.2.1.3. Mantel Cell Lymphoma
9.2.1.4. Primary Central Nervous System Lymphoma
9.2.2. T-Cell Non-Hodgkin Lymphoma
9.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
9.2.2.2. Anaplastic Large Cell Lymphoma
9.2.2.3. Angioimmunoblastic T-Cell Lymphoma
9.2.2.4. Enteropathy-Associated T-Cell Lymphoma
9.2.2.5. Adult T-Cell Lymphoma
9.2.2.6. Nasal type NK/T-Cell Lymphoma
9.2.2.7. Hepatosplenic T-Cell Lymphoma
9.3. Category of Condition Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1. Category A
9.3.2. Category B
9.3.3.  Category X
9.3.4. Category E
9.4. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1. Hospitals
9.4.2. Diagnostic Centers
9.4.3. Clinics
9.5. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.5.1. USA
9.5.2. Canada
10. Europe Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1. Lymph Node Biopsy
10.1.1.1. Immunophenotyping 
10.1.1.2. Cytogenetic Analysis
10.1.1.3. Gene Expression Profiling
10.1.1.4. Microarray Analysis
10.1.2. Physical Imaging
10.1.2.1. MRI Scanning
10.1.2.2. CT-Scan
10.1.2.3. X-rays
10.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
10.1.3. Blood Tests
10.2. Type of NHL Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.  B-Cell Non-Hodgkin Lymphoma
10.2.1.1. Diffuse Large B-Cell Lymphoma 
10.2.1.2. Burkitt Lymphoma
10.2.1.3. Mantel Cell Lymphoma
10.2.1.4. Primary Central Nervous System Lymphoma
10.2.2. T-Cell Non-Hodgkin Lymphoma
10.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
10.2.2.2. Anaplastic Large Cell Lymphoma
10.2.2.3. Angioimmunoblastic T-Cell Lymphoma
10.2.2.4. Enteropathy-Associated T-Cell Lymphoma
10.2.2.5. Adult T-Cell Lymphoma
10.2.2.6. Nasal type NK/T-Cell Lymphoma
10.2.2.7. Hepatosplenic T-Cell Lymphoma
10.3. Category of Condition Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1. Category A
10.3.2. Category B
10.3.3.  Category X
10.3.4. Category E
10.4. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Clinics
10.5. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1. Germany
10.5.2. France
10.5.3. Italy
10.5.4. Spain
10.5.5. UK
10.5.6. Rest of Europe
11. Asia Pacific Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1. Lymph Node Biopsy
11.1.1.1. Immunophenotyping 
11.1.1.2. Cytogenetic Analysis
11.1.1.3. Gene Expression Profiling
11.1.1.4. Microarray Analysis
11.1.2. Physical Imaging
11.1.2.1. MRI Scanning
11.1.2.2. CT-Scan
11.1.2.3. X-rays
11.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
11.1.3. Blood Tests
11.2. Type of NHL Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.  B-Cell Non-Hodgkin Lymphoma
11.2.1.1. Diffuse Large B-Cell Lymphoma 
11.2.1.2. Burkitt Lymphoma
11.2.1.3. Mantel Cell Lymphoma
11.2.1.4. Primary Central Nervous System Lymphoma
11.2.2. T-Cell Non-Hodgkin Lymphoma
11.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
11.2.2.2. Anaplastic Large Cell Lymphoma
11.2.2.3. Angioimmunoblastic T-Cell Lymphoma
11.2.2.4. Enteropathy-Associated T-Cell Lymphoma
11.2.2.5. Adult T-Cell Lymphoma
11.2.2.6. Nasal type NK/T-Cell Lymphoma
11.2.2.7. Hepatosplenic T-Cell Lymphoma
11.3. Category of Condition Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1. Category A
11.3.2. Category B
11.3.3.  Category X
11.3.4. Category E
11.4. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Clinics
11.5. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1. China
11.5.2. Japan
11.5.3. South Korea
11.5.4. India
11.5.5. Rest of APAC
12. Latin America Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1. Lymph Node Biopsy
12.1.1.1. Immunophenotyping 
12.1.1.2. Cytogenetic Analysis
12.1.1.3. Gene Expression Profiling
12.1.1.4. Microarray Analysis
12.1.2. Physical Imaging
12.1.2.1. MRI Scanning
12.1.2.2. CT-Scan
12.1.2.3. X-rays
12.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
12.1.3. Blood Tests
12.2. Type of NHL Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.  B-Cell Non-Hodgkin Lymphoma
12.2.1.1. Diffuse Large B-Cell Lymphoma 
12.2.1.2. Burkitt Lymphoma
12.2.1.3. Mantel Cell Lymphoma
12.2.1.4. Primary Central Nervous System Lymphoma
12.2.2. T-Cell Non-Hodgkin Lymphoma
12.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
12.2.2.2. Anaplastic Large Cell Lymphoma
12.2.2.3. Angioimmunoblastic T-Cell Lymphoma
12.2.2.4. Enteropathy-Associated T-Cell Lymphoma
12.2.2.5. Adult T-Cell Lymphoma
12.2.2.6. Nasal type NK/T-Cell Lymphoma
12.2.2.7. Hepatosplenic T-Cell Lymphoma
12.3. Category of Condition Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1. Category A
12.3.2. Category B
12.3.3.  Category X
12.3.4. Category E
12.4. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1. Hospitals
12.4.2. Diagnostic Centers
12.4.3. Clinics
12.5. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Argentina
12.5.4. Rest of Latin America
13. MEA Non-Hodgkin Lymphoma Diagnostics Market, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Type Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1. Lymph Node Biopsy
13.1.1.1. Immunophenotyping 
13.1.1.2. Cytogenetic Analysis
13.1.1.3. Gene Expression Profiling
13.1.1.4. Microarray Analysis
13.1.2. Physical Imaging
13.1.2.1. MRI Scanning
13.1.2.2. CT-Scan
13.1.2.3. X-rays
13.1.2.4. Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
13.1.3. Blood Tests
13.2. Type of NHL Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.  B-Cell Non-Hodgkin Lymphoma
13.2.1.1. Diffuse Large B-Cell Lymphoma 
13.2.1.2. Burkitt Lymphoma
13.2.1.3. Mantel Cell Lymphoma
13.2.1.4. Primary Central Nervous System Lymphoma
13.2.2. T-Cell Non-Hodgkin Lymphoma
13.2.2.1. Peripheral T-Cell Lymphoma not Otherwise Specified
13.2.2.2. Anaplastic Large Cell Lymphoma
13.2.2.3. Angioimmunoblastic T-Cell Lymphoma
13.2.2.4. Enteropathy-Associated T-Cell Lymphoma
13.2.2.5. Adult T-Cell Lymphoma
13.2.2.6. Nasal type NK/T-Cell Lymphoma
13.2.2.7. Hepatosplenic T-Cell Lymphoma
13.3. Category of Condition Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1. Category A
13.3.2. Category B
13.3.3.  Category X
13.3.4. Category E
13.4. End User Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1. Hospitals
13.4.2. Diagnostic Centers
13.4.3. Clinics
13.5. Country Analysis,  2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of MEA
14.  Competition Landscape
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, By Product Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Novartis AG (Switzerland)
14.2.2. Amgen, Inc.(U.S)
14.2.3. Abbott Laboratories, Inc.(U.S)
14.2.4. Eli Lilly and Company(U.S.)
14.2.5. AstraZeneca plc (U.K)
14.2.6. Illumina, Inc.(U.S)
14.2.7. Genoptix, Inc. (U.S.)
14.2.8. bioMeriux SA (France)
14.2.9. Pfizer, Inc. (U.S.)
14.2.10. Hoffmann-La Roche Ltd. (Switzerland)
14.2.11. GlaxoSmithKline plc (UK)
15.  Research Methodology
16.  Key Assumptions and Acronyms
  • Novartis AG (Switzerland)
  • Amgen, Inc.(U.S)
  • Abbott Laboratories, Inc.(U.S)
  • Eli Lilly and Company(U.S.)
  • AstraZeneca plc (U.K)
  • Illumina, Inc.(U.S)
  • Genoptix, Inc. (U.S.)
  • bioMeriux SA (France)
  • Pfizer, Inc. (U.S.)
  • Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc (UK)
  • Celgene corporation (U.S)

Adjacent Markets